ASO Author Reflections: Unlocking the Potential of Noncoding RNAs in Gastric Cancer: From Molecular Insights to

Chen Gu1, Zhenni ChenLiu1, Qihang Wu1

  • 1Clinical Medical College, Yangzhou University, Yangzhou, Jiangsu Province, China.

PubMed

Insights

Noncoding RNAs (ncRNAs) are key drivers of gastric cancer (GC) progression and treatment resistance. Targeting these molecules offers new diagnostic and therapeutic strategies for improving patient outcomes.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Gastric cancer (GC) poses a significant global health burden due to late detection and therapeutic resistance.
  • The molecular landscape of GC is complex, hindering effective treatment strategies.

Purpose of the Study:

  • To investigate the role of noncoding RNAs (ncRNAs) in gastric cancer (GC) progression.
  • To explore the potential of ncRNAs as diagnostic markers and therapeutic targets for GC.

Main Methods:

  • Review and analysis of current research on ncRNAs in GC.
  • Identification of specific ncRNA classes (miRNAs, lncRNAs, circRNAs) implicated in GC.

Main Results:

  • Noncoding RNAs (ncRNAs), including microRNAs (miRNAs), long noncoding RNAs (lncRNAs), and circular RNAs (circRNAs), are identified as critical regulators of GC.
  • ncRNAs play significant roles in GC development, metastasis, and resistance to chemotherapy and targeted therapies.

Conclusions:

  • ncRNAs represent promising biomarkers for early diagnosis and prognosis of GC.
  • Targeting ncRNAs holds potential for developing novel therapeutic strategies to overcome treatment resistance in GC patients.
  • Further research is needed to optimize ncRNA delivery and validate their clinical efficacy for precision medicine in GC.